RECRUITING

Remote Digital Physiologic Data Collection in Cancer: An MSK Registry Protocol

Conditions

Solid Tumor Remote Digital Physiological Data Collection Exercise Oncology 20-330

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to develop a secure method of collecting physiologic information from patients with cancer. The researchers will use this information to learn more about how physiologic data may relate to cancer diagnosis and response to treatment, and to identify factors that may lead to higher or lower risk of cancer.

Official Title

Remote Digital Physiological Data Collection in Cancer: An MSK Registry Protocol

Quick Facts

Study Start:2022-05-19

Study Completion:2025-05

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05390827

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 90 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Individuals who meet at least one of the following criteria: * Diagnosis of new onset early-stage (I-III), low-grade (I-II), or locally advanced solid tumor within 24 months of initial recruitment approach * Diagnosis of primary invasive solid tumor from 2015 onwards * Diagnosis of metastatic (stage IV) or high-grade (III-IV) disease * Enrolled onto an investigational trial in the EDD Service * Seen in the MSK UCC from 2021 and onwards * Completion of Baseline Medical History (BMH) Questionnaire * Adult without a history of cancer \<50 years of age * Adult without a history of cancer ≥ 50 years of age * 18 to 90 years old * Own an Apple iPhone with valid iOS operating software * Have the MyMSK app downloaded on their iPhone or be willing to download the MyMSK app * Willing to provide informed consent * Self-reported "very well" comprehension of written and verbal English language * Patients at MSK who are: * Scheduled to undergo any type of BMT (Cohort 1) * Diagnosed with new onset AML and scheduled to initiate antineoplastic therapy (Cohort 2) * Scheduled to undergo any surgery for prostate cancer (Cohort 3) * Scheduled to undergo any lung cancer surgery (Cohort 4) * Scheduled to undergo TNT for locally advanced rectal cancer (Cohort 5) * Scheduled to initiate androgen deprivation therapy for at least 12 months and has one of the following prostate cancer diagnoses (Cohort 6): * High risk/very high localized, locally advanced, * Biochemically recurrent prostate cancer * Treatment naïve, low-volume metastatic prostate cancer * Scheduled Scheduled to undergo chemotherapy for metastatic pancreatic cancer (Cohort 7) * Individuals without cancer \<50 years of age (Cohort 8) * Individuals without cancer ≥50 years of age (Cohort 9) * 18 to 90 years old at the time of consent * Willing and able to download the Withings Health Mate app onto their personal mobile device * Willing to provide mobile digital physiological data for a period of at least six months to a maximum of one year following consent * Willing to provide informed consent	* Unable or unwilling to successfully export and share physiological data * Unable or unwilling to appropriately use digital platforms or devices

Inclusion Criteria

Exclusion Criteria

* Individuals who meet at least one of the following criteria:
* Diagnosis of new onset early-stage (I-III), low-grade (I-II), or locally advanced solid tumor within 24 months of initial recruitment approach
* Diagnosis of primary invasive solid tumor from 2015 onwards
* Diagnosis of metastatic (stage IV) or high-grade (III-IV) disease
* Enrolled onto an investigational trial in the EDD Service
* Seen in the MSK UCC from 2021 and onwards
* Completion of Baseline Medical History (BMH) Questionnaire
* Adult without a history of cancer \<50 years of age
* Adult without a history of cancer ≥ 50 years of age
* 18 to 90 years old
* Own an Apple iPhone with valid iOS operating software
* Have the MyMSK app downloaded on their iPhone or be willing to download the MyMSK app
* Willing to provide informed consent
* Self-reported "very well" comprehension of written and verbal English language
* Patients at MSK who are:
* Scheduled to undergo any type of BMT (Cohort 1)
* Diagnosed with new onset AML and scheduled to initiate antineoplastic therapy (Cohort 2)
* Scheduled to undergo any surgery for prostate cancer (Cohort 3)
* Scheduled to undergo any lung cancer surgery (Cohort 4)
* Scheduled to undergo TNT for locally advanced rectal cancer (Cohort 5)
* Scheduled to initiate androgen deprivation therapy for at least 12 months and has one of the following prostate cancer diagnoses (Cohort 6):
* High risk/very high localized, locally advanced,
* Biochemically recurrent prostate cancer
* Treatment naïve, low-volume metastatic prostate cancer
* Scheduled Scheduled to undergo chemotherapy for metastatic pancreatic cancer (Cohort 7)
* Individuals without cancer \<50 years of age (Cohort 8)
* Individuals without cancer ≥50 years of age (Cohort 9)
* 18 to 90 years old at the time of consent
* Willing and able to download the Withings Health Mate app onto their personal mobile device
* Willing to provide mobile digital physiological data for a period of at least six months to a maximum of one year following consent
* Willing to provide informed consent

* Unable or unwilling to successfully export and share physiological data
* Unable or unwilling to appropriately use digital platforms or devices

Contacts and Locations

Study Contact

Lee Jones, PhD

CONTACT

646-888-8103

jonesl3@mskcc.org

Jessica Scott, PhD

CONTACT

646-888-8093

Principal Investigator

Lee Jones, PhD

PRINCIPAL_INVESTIGATOR

Memorial Sloan Kettering Cancer Center

Study Locations (Sites)

Memorial Sloan Kettering Cancer Center

New York, New York, 10065

United States

Collaborators and Investigators

Sponsor: Memorial Sloan Kettering Cancer Center

Lee Jones, PhD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-05-19

Study Completion Date2025-05

Study Record Updates

Study Start Date2022-05-19

Study Completion Date2025-05

Terms related to this study

Keywords Provided by Researchers

Remote Digital Physiological Data Collection
Exercise Oncology
20-330

Additional Relevant MeSH Terms

Solid Tumor